SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Lyft, Inc. engages in the provision and management of an online social rideshare community platform. It offers access to a network of shared bikes and scooters for shorter rides and first mile and last-mile legs of multimodal trips, information about nearby public transit routes, and Lyft Rentals to offer riders a view of transportation options when planning any trip. The company was founded by Marcus Cohn, John Zimmer, Rajat Suri, Matt van Horn, and Logan D. Green on March 5, 2007 and is headquartered in San Francisco, CA.

Lyft Inc - Ordinary Shares Cls A

Lyft Inc

Lyft remains a subject of intense community debate as investors weigh its potential as an acquisition target for major tech players against concerns regarding stiff competition and recent stock volatility. While some see value in the company's improved profitability and share buyback program, others are closely monitoring high short interest and evolving autonomous vehicle partnerships that continue to drive market sentiment.

iShares Trust - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is currently trading near historical lows as rising long-term Treasury yields and persistent inflationary pressures from energy markets heighten investor anxiety. Community sentiment is deeply divided, with many traders viewing the bond market's sell-off as a signal of a broader structural crisis while others see deep-value accumulation potential if economic conditions trigger a flight to safety.

SentinelOne, Inc. engages in the provision of endpoint security software that detects, models, and predicts threat behavior to block attacks on any computing device. Its services include vigilance, support, and training. The company was founded by Tomer Weingarten and Almog Cohen in 2013 and is headquartered in Mountain View, CA.

SentinelOne Inc - Ordinary Shares - Class A

SentinelOne Inc

SentinelOne is facing significant selling pressure as investors react to a soft revenue forecast and news of a corporate restructuring plan involving workforce reductions. Despite meeting earnings expectations and maintaining full-year revenue targets, the market remains skeptical, with the community actively debating whether the stock's valuation discount makes it an attractive M&A target or if management's execution continues to lag behind industry peers.

Globalstar, Inc. engages in the provision of mobile satellite services. It offers voice and data communications services to the following markets: recreation and personal, government, public safety and disaster relief, oil and gas, maritime and fishing, natural resources, mining, and forestry, construction, utilities, and transportation. The company was founded in November 2003 and is headquartered in Covington, LA.

Globalstar Inc.

Globalstar is trending as investors monitor the pending merger with Amazon, with the community actively debating whether the current deal undervalues the company's spectrum assets or if a superior, unsolicited bid could emerge from other industry giants. Discussions are centered on the significant valuation gap compared to other recent spectrum deals and the ongoing uncertainty surrounding launch schedules and regulatory milestones.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is seeing heightened investor activity following the EU approval of the oral Wegovy pill, a significant development for its competitive standing in the GLP-1 market. While the community remains divided over a recent legal challenge against Eli Lilly and potential pipeline volatility, many investors are focused on the long-term potential of the oral product launch and upcoming earnings.

Shopify, Inc. is a global commerce company that provides essential internet infrastructure for commerce, offering trusted tools to start, scale, market, and run a retail business of any size. The Company's software enables merchants to run their business across all of their sales channels, including web and mobile storefronts, physical retail locations, social media storefronts and marketplaces. The Shopify platform provides merchants with a single view of their business across all of their sales channels and enables them to manage products and inventory, process orders and payments, fulfill and ship orders, build customer relationships, source products, leverage analytics and reporting and access financing, all from one integrated back office. The company was founded on September 28, 2004 and is headquartered in Ottawa, Canada.

Shopify Inc - Ordinary Shares - Class A (Sub Voting)

Shopify Inc

Shopify is experiencing high volatility as investors weigh strong sentiment regarding its AI-driven growth and enterprise potential against concerns over valuation and broader economic headwinds. The community is actively debating whether recent share buybacks and analyst upgrades signal a long-term turnaround or if lingering litigation and market rotation pose continued downside risks.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit Therapeutics is driving intense community interest as it presents practice-changing phase III overall survival data for its bispecific antibody, ivonescimab, at the ASCO conference. Investors and analysts are actively debating the potential for this drug to disrupt the current lung cancer standard of care, despite ongoing scrutiny regarding the clinical trial populations and competition from established players.

Invesco DB US Dollar Index Bullish Fund - Invesco DB US Dollar Index Bullish Fund

Invesco DB US Dollar Index Bullish Fund

The Invesco DB US Dollar Index Bullish Fund is facing intense debate as investors weigh the impact of shifting Fed interest rate expectations against geopolitical risks and energy market volatility. Market participants are actively discussing the potential for a weakening dollar and rotating into alternative assets, driven by concerns over U.S. debt dynamics and the broader implications of monetary policy changes.

Abbott Laboratories engages in the discovery, development, manufacture, and sale of healthcare products. It operates through the following segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment focuses on branded generic pharmaceuticals that are manufactured worldwide and marketed and sold outside the United States, primarily in emerging markets. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, clinics, physicians' offices, retailers, government agencies, and alternative care testing sites. The Nutritional Products segment oversees the worldwide sale of pediatric and adult nutritional products. The Medical Devices segment offers a broad range of rhythm management, electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, as well as diabetes care and continuous glucose monitoring products. It also provides neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Abbott Laboratories

Abbott Laboratories is trending as the market evaluates its strategic expansion and long-term earnings potential, with investors closely watching for a rebound following a recent price consolidation. The community is actively debating the stock's valuation as a dependable healthcare defensive play, weighing recent insider buying against concerns related to ongoing legal developments.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is capturing significant community attention ahead of their upcoming earnings report, with investors actively discussing potential revenue beats, market share growth, and expectations for a transformative forward outlook. Sentiment remains heavily focused on the company's long-term commercial trajectory and the persistent, high-conviction narrative that the stock remains a prime candidate for an acquisition at a substantial premium.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$LIN Q2 &#39;26 Earnings Results &amp; Recap

Linde expects third-quarter 2026 adjusted diluted earnings per share in the range of $4.45 to $4.55 and full-year 2026 adjusted diluted earnings per share of $17.70 to $17.90 for Linde.

Joe Watford

Stocktwits

Linde Plc.

 Q2 '26 Earnings Results & Recap

Linde expects third-quarter 2026 adjusted diluted earnings per share in the range of $4.45 to $4.55 and full-year 2026 adjusted diluted earnings per share of $17.70 to $17.90 for Linde.

This account has been verified as an official STOCKTWITS representative.